Insights Into Multiple Myeloma (MM) 2025
Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents
Puerto Rico – February 19, 2025
Faculty Chair
Melissa Alsina, MD
Moffitt Cancer Center, Tampa, FL, USA
Southeast – March 22, 2025
Faculty Chair
Jonathan Kaufman, MD
Winship Cancer Institute, Atlanta, GA, USA
Central – April 5, 2025
Faculty Co-Chair
Larry Anderson, MD, PhD
UT Southwestern Medical Center, Dallas, TX, USA
Southwest – May 2, 2025
Faculty Chair
Doug Sborov, MD
University of Utah Health, Salt Lake City, UT, USA
More Information
- Virtual series
- Puerto Rico
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Phoenix, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- VA
- DC
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of MM
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
